Psychopharmacology of Depression in the Next Millennium

  title={Psychopharmacology of Depression in the Next Millennium},
  author={Paul J. Goodnick},
  journal={CNS Spectrums},
  pages={21 - 35}
  • P. Goodnick
  • Published 1 July 1999
  • Psychology, Biology, Medicine, Chemistry
  • CNS Spectrums
Abstract Over the last half of the 20th century, there have been a series of psychopharmacologic strategies for treatment of depression. As we approach the next century, new therapies in varying stages of American release are being developed. This review will focus on information available for the following proposed antidepressants: 1) reboxetine, a norepinephrine selective reuptake inhibitor; 2) milnacipran, a combined serotonin/norepinephrine reuptake inhibitor; 3) a new enantiomer of… 
1 Citations

Duloxetine HCl (Cymbalta) for the Treatment of Depression, Neuropathic Pain, Fibromyalgia, and Stress Urinary Incontinence

Serotonin (5-HT) and norepinephrine (NE) are neurotransmitters thought to help regulate human emotions and sensitivity to pain and when these neurotransmitter levels are not in balance, people may become depressed and may be more likely to experience painful physical symptoms.



Milnacipran and selective serotonin reuptake inhibitors in major depression

Clinical trials comparing the new SNRI milnacipran with the SSRIs fluoxetine and fluvoxamine suggest that milnadrenaline reuptake inhibitors is superior in efficacy to SSRI and is equally well tolerated, and milnACipran, therefore, appears to offer a therapeutic advantage over theSSRIs.

Antidepressant treatments in the 21st century

Reboxetine versus fluoxetine: an overview of efficacy and tolerability.

  • J. Massana
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 1998
Reboxetine is an effective and well-tolerated antidepressant and is superior to fluoxetine in the treatment of severely ill patients and in terms of improving social functioning.

Psychopharmacology of affective disorders in the 21st century.

  • C. Nemeroff
  • Biology, Psychology
    Biological psychiatry
  • 1998

Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review.

The first in its class, reboxetine, a selective NRI, will provide a valuable addition to the existing armamentarium of agents used in the treatment of depression, and was well tolerated.

Pharmacokinetics of milnacipran in comparison with other antidepressants

The pharmacokinetic characteristics of the tricyclic antidepressants, the selective serotonin reuptake inhibitors (SSRIs) and more recently introduced antidepressants such as venlafaxine and nefazodone are reviewed.

Clinical efficacy of milnacipran: placebo‐controlled trials

A subgroup analysis of hospitalized patients in the meta-analysis showed an advantage for milnacipran, suggesting that milnadrenaline reuptake inhibitor is effective in more severe depression.

Electrophysiological study of the effects of the reuptake inhibitor duloxetine on serotonergic responses in the aging hippocampus.

The pharmacological effects of the dual serotonin (5-hydroxy-tryptamine, 5-HT) and norepinephrine reuptake inhibitor, duloxetine, on serotonergic function in the aging hippocampus were studied using

Preclinical pharmacology of milnacipran

Milnacipran (Ixel) is a new antidepressant which has been developed for its selective inhibition of both serotonin and noradrenaline reuptake and its lack of affinity for neurotransmitter receptors.

Selective Serotonin/Noradrenal Reuptake Inhibitors (SNRIs)

Results need to be interpreted with caution, given the methodological difficulties in measuring appropriately the onset of antidepressant action and the few studies specifically addressing this issue, and the incidence of adverse events of SNRIs increases with dose.